A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin

A Multicenter Randomized Exploratory Clinical Trial to Evaluate the Effect of Bone Metabolism and the Efficacy of Evogliptin and Dapagliflozin for Blood Sugar in the Menopause Female Patients With Osteopenia and Type 2 Diabetes

Patrocinadores

Patrocinador principal: Kyung Hee University Hospital at Gangdong

Colaborador: Dong-A ST Co., Ltd.

Fuente Kyung Hee University Hospital at Gangdong
Resumen breve

This multi-center, randomized and exploratory clinical trial is designed to evaluate the effect of bone metabolism and blood sugar of evogliptin and dapagliflozin in the menopause female patients with osteopenia and type 2 diabetes. The trial will evaluate bone metabolism (bone markers and bone density) and blood sugar (AGE and glucose variability) after 12 weeks and 48 weeks. This clinical trial conducts in two arms, and each arm recruits 60 subjects.

Descripción detallada

This clinical trial is to evaluate the effect of bone metabolism and blood sugar of evogliptin and dapagliflozin in the menopause female patients with osteopenia and type 2 diabetes. Bone metabolism (bone markers and bone density) and blood sugar (AGE and glucose variability) after 12 weeks and 48 weeks will be evaluated. This clinical trial conducts in two arms, and each arm recruits 60 subjects. If a subject voluntarily agrees to participate and meets the inclusion and exclusion criteria for the clinical trial, the subject will be randomly assigned to one of the two arms. The total period after the subject enrollment is 48 weeks, and a total of six visits are made with screening, baseline, 12 weeks, 24 weeks, 36 weeks, and 48 weeks. Efficacy evaluation will be carried out changes on blood sugar, bone markers and density and after 12 and 48 weeks. The results of this study are intended to be a reference to future clinical trials.

Estado general Not yet recruiting
Fecha de inicio February 1, 2021
Fecha de Terminación January 31, 2023
Fecha de finalización primaria January 31, 2022
Fase Phase 4
Tipo de estudio Interventional
Resultado primario
Medida Periodo de tiempo
Change of bone density Screening, 48 weeks
Change of CTX(C-terminal telopeptide of type I collagen) Baseline, 12 weeks, 48 weeks
Change of P1NP(Procollagen type 1 Aminoterminal Propeptide) Baseline, 12 weeks, 48 weeks
Change of 25OHD(25 Hydroxyvitamin D) Baseline, 12 weeks, 48 weeks
Change of PTH(Parathyroid Hormone) Intact Baseline, 12 weeks, 48 weeks
Change of FGF23 (Fibroblast growth factor 23) Baseline, 12 weeks, 48 weeks
Change of 24 hour urine calcium Baseline, 12 weeks, 48 weeks
Change of 24 hour urine phosphate Baseline, 12 weeks, 48 weeks
Change of 24 hour urine creatinine Baseline, 12 weeks, 48 weeks
Resultado secundario
Medida Periodo de tiempo
Change of HbA1C Baseline, 12 weeks, 48 weeks
Change of FBS(Fasting Blood Sugar) Baseline, 12 weeks, 48 weeks
Change of insulin Baseline, 12 weeks, 48 weeks
Change of c-peptide Baseline, 12 weeks, 48 weeks
Change of AGE(Advanced Glycation End Products) Baseline, 12 weeks, 48 weeks
Change of CGM(Continuous Glucose Monitoring) Baseline, 12 weeks, 48 weeks
Adverse events 12 weeks, 24 weeks, 36 weeks, 48 weeks
Inscripción 120
Condición
Intervención

Tipo de intervención: Drug

Nombre de intervención: Evogliptin

Descripción: evogliptin 5mg + metformin, oral administration once a day for 48 weeks

Etiqueta de grupo de brazo: evogliptin

Tipo de intervención: Drug

Nombre de intervención: Dapagliflozin

Descripción: dapagliflozin 10mg + metformin, oral administration once a day for 48 weeks

Etiqueta de grupo de brazo: dapagliflozin

Elegibilidad

Criterios:

Inclusion Criteria: 1. Postmenopausal women between 40 and 70 years of age with type 2 diabetes patients who are not taking diabetes drugs or who are not controlled by blood sugar at 7.0≤HbA1c≤9.0 while taking metformin ※ Menopause corresponds when one or more of the following three conditions are satisfied. (1) 12 months of amenorrhea (2) In the case of FSH≥40 mIL(milli-international unit)/mL in women over 50 years who have undergone a hysterectomy or 6 months of amenorrhea (3) Patients 6 weeks after ovariectomy 2. Lumbar, neck of femur and total femur bone density measurements were -2.4≤T-score≤-1.0 3. Obtained written informed consent from a patient 4. Patients who can participate during clinical trials and perform all planned trial procedures and visits. Exclusion Criteria: 1. A person who has taken a diabetes medications other than metformin within 12 weeks, or who is hypersensitivity to DPP4(dipeptidyl peptidase-4) inhibitors or SGLT2 inhibitors. 2. AST(ASpartate Transaminase) or ALT(ALanine Transaminase) exceeds 2 times the upper limit of the normal range in laboratory tests 3. Patients with moderate or severe renal impairment, end-stage renal disease (ESRD) or dialysis 4. Patients whose eGFR(epidermal growth factor receptor) calculated using MDRD formula within 4 weeks before screening or at screening is less than 60 mL/minute/1.73 m2 5. In the case of osteoporosis medication dosage as follows: - Patients who have ever used bisphosphonate formulations - Patients who have used female hormones, SERM(Selective Estrogen Receptor Modulator), denosumab, and parathyroid hormone preparations within 12 months 6. Have bone or mineral metabolic diseases or have received treatment that affects them (1) Steroid; - Oral steroid 2.5mg or more has been continuously taken for more than 3 months from the date of consent - Continuous use of systemic or inhaled steroids for more than 3 months from the date of consent (2) Taking diuretics (3) Patients at risk for secondary osteoporosis 7. Patients who have participated in other clinical trials within 3 months 8. Patients with a history of malignant tumors within 5 years 9. Those who have a history of hypersensitivity to the main ingredients and additives of the trial drugs 10. Patients with type 1 diabetes or diabetic ketoacidosis 11. Patients with genetic problems such as galactose intolerance, Lapp deficiency, or glucose-galactose malabsorption 12. Any other patient that the investigator has determined is unsuitable for this clinical trial

Género: Female

Basado en el género: Yes

Descripción de género: menopause female patients with osteopenia and type 2 diabetes.

Edad mínima: 40 Years

Edad máxima: 70 Years

Voluntarios Saludables: No

Oficial general
Apellido Papel Afiliación
Hoyeon Chung, MD, PhD Principal Investigator Kyung Hee University Hospital at Gangdong
Contacto general

Apellido: Hoyeon Chung, MD, PhD

Teléfono: +82-2-440-6124

Email: [email protected]

Ubicación
Instalaciones: Contacto: Investigador:
GangNeung Asan Hospital | Gangneung, Gangwondo, 25440, Korea, Republic of Ha Young Kim, MD, PhD +82-33-610-3072 [email protected] Ha Young Kim, MD, PhD Principal Investigator
Inha University Hospital | Incheon, 22332, Korea, Republic of Seong Bin Hong, MD, PhD +82-32-890-3363 [email protected] Seong Bin Hong, MD, PhD Principal Investigator
Kyung Hee University Hospital | Seoul, 02447, Korea, Republic of So Young Park, MD, PhD +82-2-958-9431 [email protected] So Young Park, MD, PhD Principal Investigator
Soon Chun Hyang University Hospital Seoul | Seoul, 04401, Korea, Republic of Dong Won Byun, MD,PhD +82-2-710-4240 [email protected] Dong Won Byun, MD,PhD Principal Investigator
Konkuk University Medical Center | Seoul, 05030, Korea, Republic of Kee Ho Song, MD, PhD +82-2-2030-7533 [email protected] Kee Ho Song, MD, PhD Principal Investigator
Kyung Hee University Hospital at Gangdong | Seoul, 05278, Korea, Republic of Hoyeon Chung, MD, PhD +82-2-440-6124 [email protected] Hoyeon Chung, MD, PhD Principal Investigator
The Catholic University of Korea, Yeouido St. Mary's Hospital | Seoul, 07345, Korea, Republic of Ki Hyun Baik, MD, PhD +82-2-3779-1400 [email protected] Ki Hyun Baik, MD, PhD Principal Investigator
Ubicacion Paises

Korea, Republic of

Fecha de verificación

December 2020

Fiesta responsable

Tipo: Sponsor

Palabras clave
Tiene acceso ampliado No
Condición Examinar
Número de brazos 2
Grupo de brazo

Etiqueta: evogliptin

Tipo: Experimental

Descripción: evogliptin 5 mg + metformin, oral administration once a day for 48 weeks

Etiqueta: dapagliflozin

Tipo: Active Comparator

Descripción: dapagliflozin 10mg + metformin, oral administration once a day for 48 weeks

Acrónimo EVOMETA
Datos del paciente No
Información de diseño del estudio

Asignación: Randomized

Modelo de intervención: Parallel Assignment

Descripción del modelo de intervención: If a subject voluntarily agrees to participate and meets the inclusion and exclusion criteria for the clinical trial, the subject will be randomly assigned to one of the two arms. Arm 1: evogliptin 5mg + metformin, oral administration once a day for 48 weeks Arm 2: dapagliflozin 10mg + metformin, oral administration once a day for 48 weeks

Propósito primario: Treatment

Enmascaramiento: None (Open Label)

Descripción de enmascaramiento: The subject will be randomly assigned to one of the two arms. This is an open-label trial.

Fuente: ClinicalTrials.gov